Pierre Laurent-Puig
Overview
Explore the profile of Pierre Laurent-Puig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
346
Citations
20261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nasca V, Zhao J, Ros J, Lonardi S, Zwart K, Cohen R, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39929672
Background: Immune checkpoint inhibitors (ICIs) are the gold standard therapy in patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). A significant proportion of patients show resistance,...
2.
Sullo F, Garinet S, Blons H, Taieb J, Laurent-Puig P, Gallois C
Crit Rev Oncol Hematol
. 2025 Feb;
208:104656.
PMID: 39922396
Colorectal cancer (CRC) is the third leading cause of cancer death and accounts for 10 % of cancer diagnoses worldwide. Despite the advancements achieved over the latest decades, CRC treatments...
3.
Taieb J, Souglakos J, Boukovinas I, Falcoz A, Pages F, Messaritakis I, et al.
J Clin Oncol
. 2025 Feb;
:JCO2400648.
PMID: 39903903
Purpose: Immunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication and tailoring adjuvant treatments in patients resected from a stage III colon cancer (CC). Here,...
4.
Gallois C, Sroussi M, Andre T, Mouillet-Richard S, Agueeff N, Mulot C, et al.
J Clin Oncol
. 2025 Jan;
:JCO2302262.
PMID: 39889251
Purpose: The objective of this work was to establish prognostic models in stage III colon cancer (CC) on the basis of transcriptomic signatures of the tumor microenvironment (TME) and cell...
5.
Azais H, Brochard C, Taly V, Benoit L, Ferron G, Ray-Coquard I, et al.
Gynecol Oncol
. 2024 Dec;
192():145-154.
PMID: 39671779
Objective: To evaluate the prognostic impact of circulating tumor DNA (ctDNA) detection at diagnosis (T0) and its early decrease after one cycle (T1) of neoadjuvant chemotherapy (NACT) in patients with...
6.
Paolini L, Tran T, Corgnac S, Villemin J, Wislez M, Arrondeau J, et al.
J Immunother Cancer
. 2024 Dec;
12(12.
PMID: 39631852
Background: A high density of resident memory T cells (T) in tumors correlates with improved clinical outcomes in immunotherapy-treated patients. In most clinical studies, T are defined by the CD103...
7.
Pilati C, Soulabaille A, Gallois C, Blons H, Cayre A, Sroussi M, et al.
Gastroenterology
. 2024 Nov;
PMID: 39612956
Background & Aims: ERBB2 pathway activation, through amplification or activating mutations, represents a new target for colon cancer (CC) treatment. Molecular methods were compared with the gold standard for assessing...
8.
Gandini A, Taieb J, Blons H, Netter J, Laurent-Puig P, Gallois C
Cancer Treat Rev
. 2024 Sep;
130:102821.
PMID: 39236404
Colorectal cancer that occurs before age of 50 is defined as Early-Onset Colorectal Cancer (EOCRC). Its incidence has worryingly increased since the late 90 s and is expected to keep...
9.
Lailler C, Didelot A, Garinet S, Berthou H, Sroussi M, De Reynies A, et al.
Oncogene
. 2024 Aug;
43(37):2781-2794.
PMID: 39147880
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit from treatment with tyrosine kinase inhibitors (TKI) targeting EGFR. Despite improvements in patient care, especially with the 3rd generation TKI osimertinib,...
10.
Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments
Campani C, Imbeaud S, Couchy G, Ziol M, Hirsch T, Rebouissou S, et al.
Gut
. 2024 Jul;
73(11):1870-1882.
PMID: 39054058
Objective: Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). Design: We analysed 772...